Global Colony Stimulating Factors Market

Report ID : 1382 | Published : 2022-10-04 | Pages: | Format: PDF/EXCEL

The market size of the Global Colony Stimulating Factors Market is predicted to grow at an 7.27% CAGR during the forecast period.

Colony stimulating factors (CSFs) are proteins that resemble hormones and encourage the development of immune cells that can fight infections. Human bodies manufacture CSFs from various cells, which can travel throughout the body and attach to cells with specific CSF receptors. CSFs can stimulate the synthesis of immune cells, which makes them useful as medications to boost the production of white blood cells. This could be a life-saving medication for patients whose immune systems have been destroyed by chemotherapy or specific immunodeficiency diseases. The primary factors propelling the growth of the global market for colony-stimulating factors are the rise in governmental funding for healthcare, rising cancer prevalence, and awareness of the availability of different cancer treatment alternatives. The growing need for prophylactic colony-stimulating factors is another significant reason for the market's expansion.

It is projected that improvements and advancements in genomics technology and healthcare will drive market expansion throughout the forecast period. Ongoing research and development of new cancer medicines and treatments for their side effects drive market growth. However, the market's growth is constrained by stringent government regulations for the approval of any new treatment options. The high cost is one of the critical obstacles limiting the CSF market from growing.

Market Segmentation:

The Colony Stimulating Factors market is segmented on type, drug, application, dosage, route of administration, end-users and distribution channel. Based on type, the market is segmented into Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF) and Granulocyte–Colony-Stimulating Factor (G-CSF). Based on the drug, the Colony Stimulating Factors are segmented into Pegfilgrastim, Tbo-filgrastim, Sargramostim and Filgrastim. Based on the application, the Colony Stimulating Factors are segmented into Aplastic Anemia, Bone Marrow Transplantation, Neutropenia, Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation and Peripheral Progenitor Cell Transplantations. Based on dosage, the Colony Stimulating Factors are segmented into Injection, Tablets, Capsules and Others. Based on route of administration, the market is segmented into Intravenous, Subcutaneous, Oral and Others. Based on end-user, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others.

Based on type, the Granulocyte–Colony-Stimulating Factor (G-CSF) segment is accounted as a significant contributor to the Colony Stimulating Factors market.

Based on type, the market is segmented into Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF) and Granulocyte–Colony-Stimulating Factor (G-CSF). The Granulocyte–Colony-Stimulating Factor (G-CSF) segment dominated the market. Following chemotherapy, the drug Granulocyte Colony-stimulating Factor (G-CSF) is used to treat cancer. Granulocyte-colony stimulating factor (G-CSF) is a glycoprotein that encourages the production of stem cells and granulocytes in the bone marrow and their release into the blood.

The Pegfilgrastim segment witnessed growth at a rapid rate.

Based on the drug, the Colony Stimulating Factors are segmented into Pegfilgrastim, Tbo-filgrastim, Sargramostim and Filgrastim. The Pegfilgrastim segment dominated the market. Treating neutropenia (low white blood cells) brought on by cancer medications involves the injection of pegfilgrastim. It is a man-made version of a substance known as a colony-stimulating factor created naturally in your body. White blood cell production in the bone marrow is boosted by pegfilgrastim.

The North America Colony Stimulating Factors market holds a significant regional revenue share.

The North America Colony Stimulating Factors market is expected to register the highest market share in revenue in the near future. Some factors contributing to its highest share include the availability of well-established healthcare facilities and many individuals suffering from blood disorders. Furthermore, increased R&D initiatives to create new products will likely boost growth during the projection period. In addition, Asia Pacific is projected to grow rapidly in the global Colony Stimulating Factors market because of rising chronic illness occurrences, rising per capita income, greater access to healthcare facilities, treatment rates for GWCF medications such as granulocyte colony-stimulating (G-CSF) factor have increased. Additionally, growing public awareness of chronic diseases will fuel demand in this region.

Competitive Landscape

Some major key players in the Colony Stimulating Factors market are Intas Pharmaceuticals Ltd., Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., GlaxoSmithKline plc, Biocon, Dr. Reddy's Laboratories Ltd., Amgen Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Stada Arzneimittel AG, Emcure Pharmaceuticals Limited., Celltrion, Inc, Biocad, Coherus BioSciences, Johnson & Johnson Private Limited, Eli Lilly and Company and Abbott.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Colony Stimulating Factors Market Snapshot

Chapter 4. Global Colony Stimulating Factors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis

5.1. by Product Type & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Product Type:

5.2.1. Macrophage–Colony-Stimulating Factor (M-CSF)

5.2.2. Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3)

5.2.3. Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)

5.2.4. Granulocyte–Colony-Stimulating Factor (G-CSF)

Chapter 6. Market Segmentation 2: by Drug Estimates & Trend Analysis

6.1. by Drug & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Drug:

6.2.1. Pegfilgrastim

6.2.2. Tbo-filgrastim

6.2.3. Sargramostim

6.2.4. Filgrastim

Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis

7.1. by Application & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Application:

7.2.1. Aplastic Anemia

7.2.2. Bone Marrow Transplantation

7.2.3. Neutropenia

7.2.4. Neutropenia Associated with Chemotherapy

7.2.5. Neutropenia Associated with Radiation

7.2.6. Peripheral Progenitor Cell Transplantations

Chapter 8. Market Segmentation 4: by Dosage Estimates & Trend Analysis

8.1. by Dosage & Market Share, 2019 & 2030

8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Dosage:

8.2.1. Injection

8.2.2. Tablets

8.2.3. Capsule

8.2.4. Others

Chapter 9. Market Segmentation 5: by Route of Administration Estimates & Trend Analysis

9.1. by Route of Administration & Market Share, 2019 & 2030

9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Route of Administration:

9.2.1. Intravenous

9.2.2. Subcutaneous

9.2.3. Oral

9.2.4. Others

Chapter 10. Market Segmentation 6: by End-users Estimates & Trend Analysis

10.1. by End-users & Market Share, 2019 & 2030

10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by End-users:

10.2.1. Hospitals

10.2.2. Specialty Clinics

10.2.3. Homecare

10.2.4. Others

Chapter 11. Colony Stimulating Factors Market Segmentation 7: Regional Estimates & Trend Analysis

11.1. North America

11.1.1. North America Colony Stimulating Factors Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2022-2030

11.1.2. North America Colony Stimulating Factors Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2022-2030

11.1.3. North America Colony Stimulating Factors Market revenue (US$ Million) by Application, 2022-2030

11.1.4. North America Colony Stimulating Factors Market revenue (US$ Million) by Dosage, 2022-2030

11.1.5. North America Colony Stimulating Factors Market revenue (US$ Million) by Route of Administration, 2022-2030

11.1.6. North America Colony Stimulating Factors Market revenue (US$ Million) by End-users, 2022-2030

11.1.7. North America Colony Stimulating Factors Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

11.2. Europe

11.2.1. Europe Colony Stimulating Factors Market revenue (US$ Million) by Product Type, 2022-2030

11.2.2. Europe Colony Stimulating Factors Market revenue (US$ Million) by Drug, 2022-2030

11.2.3. Europe Colony Stimulating Factors Market revenue (US$ Million) by Application, 2022-2030

11.2.4. Europe Colony Stimulating Factors Market revenue (US$ Million) by Dosage, 2022-2030

11.2.5. Europe Colony Stimulating Factors Market revenue (US$ Million) by Route of Administration, 2022-2030

11.2.6. Europe Colony Stimulating Factors Market revenue (US$ Million) by End-users, 2022-2030

11.2.7. Europe Colony Stimulating Factors Market revenue (US$ Million) by country, 2022-2030

11.3. Asia Pacific

11.3.1. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) by Product Type, 2022-2030

11.3.2. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) by Drug, 2022-2030

11.3.3. Asia-Pacific Colony Stimulating Factors Market revenue (US$ Million) by Application, 2022-2030

11.3.4. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) by Dosage, 2022-2030

11.3.5. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) by Route of Administration, 2022-2030

11.3.6. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) by End-users, 2022-2030

11.3.7. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) by country, 2022-2030

11.4. Latin America

11.4.1. Latin America Colony Stimulating Factors Market revenue (US$ Million) by Product Type, 2022-2030

11.4.2. Latin America Colony Stimulating Factors Market revenue (US$ Million) by Drug, 2022-2030

11.4.3. Latin America Colony Stimulating Factors Market revenue (US$ Million) by Application, 2022-2030

11.4.4. Latin America Colony Stimulating Factors Market revenue (US$ Million) by Dosage, 2022-2030

11.4.5. Latin America Colony Stimulating Factors Market revenue (US$ Million) by Route of Administration, 2022-2030

11.4.6. Latin America Colony Stimulating Factors Market revenue (US$ Million) by End-users, 2022-2030

11.4.7. Latin America Colony Stimulating Factors Market revenue (US$ Million) by country, 2022-2030

11.5. Middle East & Africa

11.5.1. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) by Product Type, 2022-2030

11.5.2. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) by Drug, 2022-2030

11.5.3. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) by Application, 2022-2030

11.5.4. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) by Dosage, 2022-2030

11.5.5. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) by Route of Administration, 2022-2030

11.5.6. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) by End-users, 2022-2030

11.5.7. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) by country, 2022-2030

Chapter 12. Competitive Landscape

12.1. Major Mergers and Acquisitions/Strategic Alliances

12.2. Company Profiles

12.2.1. Intas Pharmaceuticals Ltd.

12.2.2. Sanofi

12.2.3. Novartis AG

12.2.4. Teva Pharmaceutical Industries Ltd.

12.2.5. Pfizer, Inc.

12.2.6. GlaxoSmithKline plc

12.2.7. Biocon

12.2.8. Dr. Reddy's Laboratories Ltd.

12.2.9. Amgen Inc.

12.2.10. Merck KGaA

12.2.11. Takeda Pharmaceutical Company Limited

12.2.12. Thermo Fisher Scientific Inc.

12.2.13. Stada Arzneimittel AG

12.2.14. Emcure Pharmaceuticals Limited.

12.2.15. Celltrion, Inc

12.2.16. Biocad

12.2.17. Coherus BioSciences

12.2.18. Johnson & Johnson Private Limited

12.2.19. Eli Lilly and Company.

12.2.20. Abbott

12.2.21. Other Prominent Players

By Type-

  • Macrophage–Colony-Stimulating Factor (M-CSF)
  • Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3)
  • Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
  • Granulocyte–Colony-Stimulating Factor (G-CSF)

By Drug-

  • Pegfilgrastim
  • Tbo-filgrastim
  • Sargramostim
  • Filgrastim

By Application-

  • Aplastic Anemia
  • Bone Marrow Transplantation
  • Neutropenia
  • Neutropenia Associated with Chemotherapy
  • Neutropenia Associated with Radiation
  • Peripheral Progenitor Cell Transplantations

By Dosage-

  • Injection
  • Tablets
  • Capsule
  • Others

By Route of Administration-

  • Intravenous
  • Subcutaneous
  • Oral
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients